Is Clearside Biomedical, Inc. overvalued or undervalued?

As of 14 August 2023, the valuation grade for Clearside Biomedical, Inc. has moved from does not qualify to risky. The company is considered overvalued based on its negative valuation ratios, including a Price to Book Value of -1.33, an EV to EBIT of -3.91, and an EV to EBITDA of -3.96. In comparison to peers, Kinnate Biopharma, Inc. has a fair valuation with a P/E of -1.1313, while Veru, Inc. is also rated risky with an EV to EBITDA of -1.1714.
Despite the recent surge in stock price, with a 1-week return of 1012.70% compared to the S&P 500's 1.05%, the overall financial metrics indicate that Clearside Biomedical, Inc. is not positioned favorably within its industry. The combination of negative ratios and a risky valuation grade suggests that investors should approach this stock with caution.